• Home
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Services
  • Franchise
  • About
Medicap - Home
Find a Pharmacy Health News Medications Conditions RxCoupons Services Franchise About

Blindness Macular DegenerationInfo Center

At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.


Cancer Drug Reaffirmed for Macular Degeneration
A second trial has affirmed that cancer drug Avastin ( bevacizumab ) is an effective cost efficient treatment for patients suffering from age-related macular degeneration (AMD), which can lead to blindness.
IV Drugs Equal for Treating Macular Degeneration
Two medications commonly used to treat age-related macular degeneration (AMD) have been found to provide equal treatment benefit in the first long-term study comparing the drugs.  Injectable drugs Avastin ( bevacizumab ), an off-label cancer medication most frequently used to treat AMD, and Lucentis ( ranibizumab ), approved to treat AMD by the U.S. Food and Drug Administration in 2006, both provided similar vision improvements at two years. Get regular vision exams to pinpoint vision loss early. Maureen Maguire, PhD, corresponding author and director of the Center for Preventi...

REFINE

  • medications
      • (-) Remove Avastin filter Avastin
All information on this site is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk.
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Mobile App
  • Terms and Conditions
  • Privacy Policy
  • Services
  • Franchise
  • About
© 2020 Digital Pharmacist Inc.